PDCD1 and head and neck squamous cell carcinoma: A multicenter prospective phase II trial that evaluated the efficacy and safety of paclitaxel + biweekly Cmab in patients with RM-HNSCC previously treated with both platinum and an anti-PD-1 antibody reported an ORR of 68.7% (95% CI 49.9-83.8), a median PFS of 5.7 months, and a median OS of 13.4 months.32 Our results regarding the efficacy of treatment with PTX + Cmab are consistent with those previously reported.